NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

9560	Companies
188848	Keywords
120587	Articles
100788	Press releases

Home
Companies
NanoViricides, Inc.

PRESS RELEASE

published on 05/22/2025 at 12:30, 6 months 29 days ago

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan
NanoViricides, Inc. comments on the new COVID Vaccine Booster Shots policy adopted by the US FDA with focus on specific high-risk groups. Dr. Anil Diwan emphasizes evidence-based decision making for vaccine boosters

NanoViricides Inc. COVID Vaccine Booster Shots US FDA Policy Vaccine Effectiveness Dr. Anil Diwan
BRIEF

published on 05/16/2025 at 12:35, 7 months 4 days ago

NanoViricides fait progresser l'antiviral NV-387 dans les essais de phase II

Essai De Phase II Mise À Jour Financière Antiviral À Large Spectre Traitement MPox Épidémie De Rougeole
BRIEF

published on 05/16/2025 at 12:35, 7 months 4 days ago

NanoViricides Advances Antiviral NV-387 in Phase II Trials

Phase II Trial Financial Update Broad-spectrum Antiviral MPOX Treatment Measles Outbreak
PRESS RELEASE

published on 05/16/2025 at 12:30, 7 months 4 days ago

NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu
NanoViricides, Inc. reports filing Form 10-Q for quarter ending March 31, 2025 with SEC. Clears Phase II trial for NV-387 drug to treat MPox disease & explores Measles and Bird Flu treatments. Company has strong financials

NanoViricides NV-387 Financials Form 10-Q Phase II Trial
BRIEF

published on 05/14/2025 at 12:35, 7 months 6 days ago

NanoViricides progresse avec le médicament antiviral à large spectre NV-387

Médicaments Antiviraux Traitement MPox Épidémie De Rougeole Développement NV-387 Stratégie Mondiale En Matière De Santé
BRIEF

published on 05/14/2025 at 12:35, 7 months 6 days ago

NanoViricides Advances with Broad-Spectrum Antiviral Drug NV-387

Antiviral Drugs MPOX Treatment Measles Outbreak NV-387 Development Global Health Strategy
PRESS RELEASE

published on 05/14/2025 at 12:30, 7 months 6 days ago

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution
NanoViricides, Inc. explains its drug strategy for combating viral infections and pandemics, focusing on development of antiviral nanomedicine drugs like NV-387

NanoViricides NV-387 Antiviral Nanomedicine Viral Infections
BRIEF

published on 05/08/2025 at 12:35, 7 months 12 days ago

Approbation de l'essai clinique de phase II du NV-387 de NanoViricides en RDC

NV-387 Essai Clinique Mpox Médicament Antiviral République Démocratique Du Congo
BRIEF

published on 05/08/2025 at 12:35, 7 months 12 days ago

Approval for NanoViricides' NV-387 Phase II Clinical Trial in DRC

NV-387 Clinical Trial Antiviral Drug Mpox Democratic Republic Of Congo
PRESS RELEASE

published on 05/08/2025 at 12:30, 7 months 12 days ago

Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo
NanoViricides, Inc. receives approval from CNES for Phase II clinical trial of NV-387 in DRC for MPox disease treatment. CEO highlights drug's broad-spectrum antiviral capabilities

NanoViricides, CNES Approval, Phase II Clinical Trial, NV-387, MPox Disease

Accesswire

Published on 12/20/2025 at 00:30, 17 hours 33 minutes ago

Alphinat Announces a Profit of $120,155 for Fiscal Year Ended August 31, 2025
Published on 12/19/2025 at 22:00, 20 hours 3 minutes ago

GMV Minerals Inc. Closes Non-Brokered Equity Financing
Published on 12/19/2025 at 18:30, 23 hours 33 minutes ago

Eagle Plains Shareholders Approve all Matters at Annual General Meeting
Published on 12/19/2025 at 14:40, 1 day 3 hours ago

Northern Superior Announces Closing of the Arrangement
Published on 12/19/2025 at 13:30, 1 day 4 hours ago

Quartz Commences Trading On The OTCQX Best Market Under The Symbol QZMRF

View all ACCESSWIRE

EQS Group

Published on 12/20/2025 at 16:45, 1 hour 18 minutes ago

Shanghai Electric Powers Up Iraq's Energy Future with Major 625MW Efficiency Upgrade
Published on 12/20/2025 at 10:05, 7 hours 58 minutes ago

FITUR 2026 highlights the strong synergies between Germany and Spain
Published on 12/19/2025 at 22:03, 20 hours ago

EAMD: Trading resumes on the Düsseldorf Stock Exchange, lawsuit filed by minority shareholders dismissed, capital increase for investments in drone projects in the defense tech sector
Published on 12/19/2025 at 21:40, 20 hours 23 minutes ago

IMG Saxony-Anhalt: 2026 in Sight - Saxony-Anhalt Sets the Pace for Future Industries
Published on 12/19/2025 at 20:35, 21 hours 28 minutes ago

Nobu Manchester breaks ground as Robert De Niro visits Manchester with Salboy

Les Echos

Published on 12/19/2025 at 21:57, 20 hours 6 minutes ago

Mise à disposition du document d’enregistrement universel
Published on 12/19/2025 at 08:30, 1 day 9 hours ago

Share capital decrease by way of treasury shares cancellation
Published on 12/19/2025 at 08:30, 1 day 9 hours ago

Réduction du capital par voie d’annulation d’actions propres
Published on 12/19/2025 at 07:00, 1 day 11 hours ago

EURAZEO ANNONCE AVOIR MENÉ AVEC SUCCÈS UNE TRANSACTION ACCÉLÉRANT SA ROTATION D'ACTIFS
Published on 12/19/2025 at 07:00, 1 day 11 hours ago

EURAZEO ANNOUNCES A SUCCESSFUL TRANSACTION ACCELERATING ITS ASSET ROTATION

View all LES ECHOS COMFI WIRE